F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
复制标题
DOI：
10.1073/pnas.1608304113
复制
发表时间：
2016-11-08
影响因子：
11.1
通讯作者：
Birch, Mike
中科院分区：
文献类型：
--
作者：
Oliver, Jason D.;Sibley, Graham E. M.;Birch, Mike
有一个重要的医疗需求，新的抗真菌药物与新的作用机制，以治疗越来越多的患者威胁生命的系统性真菌疾病，并克服日益增长的问题，目前的治疗耐药。F901318是一类新型药物的主要代表，orotomides是一种临床开发的抗真菌药物，对广泛的二型和丝状真菌表现出优异的效力。F901318对来自四种主要致病曲霉属的100多种菌株的体外敏感性试验。显示最低抑制浓度的
There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of